M A C R O P H A G E -U P E C I N T E R P L A Y I N U T I
Macrophages, an immune cell type prevalently involved in innate immunity, have been detected in the urine of UTI patients [8] . Recently, new discoveries have been made about the role of macrophages in UTI. Two distinct types of macrophages have been shown to play a protective role in bacterial cystitis. Tissueresident sentinel macrophages sensed UPEC and produced chemokines to attract neutrophils and blood monocytes to the bladder connective tissue. Blood monocytes differentiated into inflammatory macrophages and secreted tumour necrosis factor a, which allowed the resident macrophages to produce a licensing signal for neutrophils. This immunologic helper signal gave neutrophils permission to access infected uroepithelium and fight the infection. The cooperative crosstalk between sentinel and helper macrophages may ensure bladder tissue protection from overly high, harmful immune response while ensuring effective UPEC clearance in primary UTI [9] .
The situation looks different in urinary tract reinfection, when adaptive immunity comes into play. In this case, macrophages have been reported to be detrimental because they impair the adaptive immune response [10] . In that study, the depletion of macrophages expressing macrophage colony-stimulating factor receptor improved bacterial clearance upon urinary tract reinfection, unless the mice lacked lymphocytes, suggesting that the macrophages were interfering with the adaptive immune response. Contrary to expectations, the numbers of T and B cells were not increased upon macrophage depletion even though these are the main effector cells of adaptive immunity. Thus the exact mechanism by which macrophages are proposed to subvert adaptive immunity is yet to be identified.
In conclusion, in primary murine UTI, macrophages are beneficial, while in urinary tract reinfection, UPEC seem to possess the means to evade the adaptive immune response [10] .
Are macrophages losing the race?
Phagocytes are considered one of the oldest types of immune cells, with macrophage-like cells present already in primitive sponges. It is estimated that some genes involved in the innate immune response developed as early as 500-600 million years ago in early invertebrate ancestors [11] . Given that some bacteria (including E. coli) can survive inside macrophages, it is conceivable that the macrophages somehow stayed behind certain E. coli strains in the evolutionary weapons race. A recent study used next-generation sequencing to investigate genome changes of macrophages and of two UPEC strains: UTI89, which can survive inside macrophages, and 83972, which cannot. UTI89 is prevalent in cystitis and 83972 is prevalent in asymptomatic bacteriuria isolates. While macrophages responded to both bacterial strains in a relatively similar manner, different bacterial strains behaved differently after they invaded the macrophages. Among genes that were upregulated only in UTI89 and not in 83972 were genes encoding for flagellarelated proteins, genes protective against oxidative stress and phage shock proteins (Psps) [12] . Psps protect the bacteria from changes in pH and extracytoplasmic stress [13] . Importantly, mutation in PspA (part of the Psp family) decreased intramacrophage survival of UTI89 [12] . The functional significance of the other genetic changes is yet to be determined. In conclusion, it seems that the UTI89 strain is ahead of macrophages in the evolutionary race, while 83972 seems to stay behind. On the other hand, UTI89 can be cured with antibiotics, while 83972 assumes a more symbiotic strategy, avoids clinical detection and therefore it is rarely exposed to antibiotic treatment.
UPEC disrupts NLRP3 inflammasome activation
NACHT leucin-rich repeat PYD protein 3 (NLRP3) is a cytosolic pattern recognition receptor, predominantly present in macrophages, that can form a protein complex called the inflammasome that mediates, together with the adapter molecule apoptosis-associated speck-like protein (ASC), caspase-1 activation. Caspase-1 cleaves the pro-inflammatory cytokine interleukin (IL)-1b to its active form and also causes a form of lytic inflammatory cell death called pyroptosis [14] .
A recent study hypothesized that UPEC weakens NLRP3 inflammasome activity, resulting in a reduction of IL-1b secretion to promote intracellular survival in uroepithelial cells [15] . To address this, researchers utilized the UPEC strain CFT073, which expresses Toll/IL-1 receptor-containing protein C (TcpC). They showed in vitro that the TcpC gene reduced caspase-1 cleavage and secretion of mature IL-1b in CFT073-infected host cells by inhibiting the NLRP3 inflammasome. Nevertheless, the inflammasome components ASC, NLRP3 and IL-1b were upregulated in CFT073-infected bladder epithelial cells in vivo. Moreover, in a model of murine UTI, TcpC present in mice infected with CFT073 reduced urinary IL-1b levels. These effects were proposed to be mediated by binding of TcpC to NLRP3 and caspase-1, thereby forming an alternative trimolecular inflammasome complex consisting of TcpC, NLRP3 and caspase-1. Taken together, these results suggest a new pathway of how UPEC might attenuate NLRP3 inflammasome activation during cystitis. Furthermore, the researchers also proposed how UPEC might utilize TcpC to escape the host defense. However, it should be noted that TcpC also interferes with TLR4 signaling [16] , and TLR4 polymorphism/differences in expression level result in differences in UTI susceptibility [17, 18] . Thus children with asymptomatic bacteriuria displayed lower TLR4 expression levels compared with healthy controls [19] .
Another study provided information about the heterogeneity of UPEC strains with respect to inflammasome activation [20] . Some UPEC strains (e.g. the CFT073 strain) triggered inflammasome activation and cell death, whereas others did not. Moreover, differences between mouse and human macrophages were discovered, highlighting the importance of the genetic complexity and the existing differences between mouse and human immune cells.
Besides its function in antimicrobial immunity, NLRP3 is not exclusively activated by bacteria; it is also important for inflammation in response to various large molecular complexes, especially crystals [21] . Thus an NLRP3-specific inflammasome inhibitor was recently shown to attenuate kidney fibrosis in a mouse model of crystal nephropathy [22] .
Therefore, promoting intrarenal inflammasome activation may not be an optimal strategy to combat UTI, because renal fibrosis may occur as a side effect.
In summary, a better understanding of pathogen subversion strategies for suppression of inflammasome activation will be a crucial puzzle piece and provide benefits for pathogen clearance and prevention of structural organ defects.
Innate-like, mucosal-associated invariant T cells play a beneficial role in UTI Mucosal-associated invariant T cells (MAITs) have recently gained much attention as immune effectors. They constitute 1-8% of T cells in human blood, intestinal mucosa and mesenteric lymph nodes [23] . In 2010, MAITs were shown to be activated by cells infected with bacteria or yeast. Moreover, patients with bacterial infections had lower numbers of MAITs in the blood, suggesting that these cells locate to the infected tissues [24] . In 2015, MAITs were detected in the urine of UTI patients [25] . Consistent with the human data, the cells accumulated in the bladder of mice infected with UPEC at Days 2 and 7 post-infection. Furthermore, the authors noticed that MR1
À/À mice that lack MAITs suffered from exacerbated UTIs when compared with mice in which MAITs were present in high numbers [25] . It has been shown that MAITs can detect and lyse epithelial cells infected with Shigella flexneri [26] . Considering that UPEC form intracellular colonies to evade killing by neutrophils [27] , it is conceivable that MAITs make the bacteria again available for phagocytosis. Whether this or other mechanisms play a role in MAIT-mediated defense against UPEC remains to be addressed in further studies.
Kynurenines impair polymorphonuclear chemotaxis
Immune cells are auxotrophic for most amino acids, including tryptophan. Consequently, they have to acquire tryptophan for their growth and activation [28] . Indoleamine 2,3-dioxygenase (IDO) catabolizes tryptophan and generates several metabolites, which are referred to as kynurenines. Besides its importance in metabolism, several studies have suggested the participation of IDO in local immunoregulation by controlling tryptophan concentrations [29] . Taking all this into account, it is not surprising that IDO and the kynurenines are a target for bacteria to disarrange this nutritive pathway.
Loughman et al. [30] previously showed that UPEC induce the expression of IDO in vitro and in a murine model of bacterial cystitis, resulting in suppression of neutrophil migration. In a recent study, they investigated whether this is due to a tryptophan limitation during host and bacteria competition or mediation by kynurenine activity [31] . In fact, transepithelial neutrophil migration was inhibited by L-kynurenine.
Furthermore, mice lacking the transcription factor aryl hydrocarbon receptor (AHR), a receptor for kynurenine [32] , and infected with UPEC showed a higher neutrophil influx [31] .
In conclusion, these studies suggested that IDO and kynurenines may allow UPEC to escape from the innate host defense in UTI. Nevertheless, no changes in bacterial load in the bladders of AHR-as well as IDO-deficient mice were detected after infection, indicating that targeting this hypothetical mechanism alone is insufficient to improve antibacterial defense [30] .
C5a/C5aR1 is detrimental in chronic kidney inflammation
The complement system comprises a great variety of plasma proteins to provide defense against infections. It detects pathogens, initiates local inflammatory reactions, recruits leucocytes, directly destroys microbes and contributes to the removal of apoptotic cells and immune complexes. It has been previously reported that UPEC unexpectedly utilize complement C3 components secreted by the urothelium to facilitate colonization of the urinary tract [33] , implying that complement activation may be disadvantageous in this particular bacterial infection.
Complement activation generates soluble mediators such as C5a, which interacts with its corresponding receptor C5aR1 and mediates recruitment and activation of leucocytes [34] , especially neutrophils. C5aR1 is strongly expressed in resident and inflammatory cells of the kidney [35, 36] . Considering the persistent bacterial load in chronic pyelonephritis, Choudhry et al. [34] hypothesized that C5aR1 may play a role in chronic kidney infection. To investigate this, they infected mice with a UPEC strain isolated from a human patient with chronic pyelonephritis. Remarkably, they noted a significantly reduced bacterial load and decreased renal injury in kidneys of C5aR1-deficient mice and mice treated with a C5aR1 antagonist (PMX53). They further demonstrated that kidneys of such mice contained fewer monocytes and macrophages but a regular neutrophil cell count.
Consistent with this, in vitro investigations revealed that C5a treatment reduced the bactericidal activity of macrophages, although it did not affect their bacterial uptake capacities, suggesting a negative effect on phagocytic function after C5a/C5aR1 interaction.
In conclusion, these studies suggest a role of C5a/C5aR1 in chronic pyelonephritis and the assumption that blockade of C5aR1 increases the capacities of bacterial removal. An open question is to clarify whether elevated levels of C5a promote kidney injury due to direct effects or through persistent bacterial exposition.
Ribonuclease 7 (RNase 7) protects urothelial cells from UPEC
Antimicrobial peptides act as a potent, natural defense against pathogens [37] . RNase 7 is expressed by various cells in the human urinary tract. Additionally, RNase 7 is one of the most abundant and most potent antimicrobial peptide found in human urine [38, 39] . Urinary RNase 7 was recently found to be decreased in type 1 diabetes mellitus (T1DM) patients with recent disease onset. Additionally, insulin treatment increased urinary RNase 7. Consistent with these findings, the authors showed that the insulin receptor and RNase 7 are both expressed by human bladder urothelium and kidney collecting tubules. Moreover, in vitro insulin treatment induced RNase 7 expression via PI3K/AKT. Importantly, media from human renal epithelial cells treated with insulin suppressed UPEC growth more efficiently than control media and this effect was mediated by RNase 7. Additionally, insulin-induced RNase 7
protected human renal epithelial cells from UPEC cytolytic activity in vitro. Interestingly, UPEC strain UTI89, which expresses a-hemolysin, interfered with PI3K/AKT signaling and suppressed RNase 7 production by the urothelial cell line [40] . In conclusion, optimizing RNase 7 concentration in the urinary tract may constitute a new therapy against more difficult urinary tract pathogens and therefore put us ahead in the evolutionary race.
Further remarkable findings in UTI
Recently reported insights into the pathophysiological processes of UTI have provided clues for novel immunomodulatory therapies. Moriel et al. [41] identified a UPEC protein named IrmA, which showed structural similarities with several human cytokine receptors and was even able to bind to IL-2, IL-4 and IL-10, suggesting IrmA as a potential target for vaccination.
However, this very interesting study contained only an in vitro readout.
Besides vaccines, bacterial toxins might represent therapeutic targets. A recently published study demonstrated a reduction of inflammation in acute cystitis after application of antibodies against hemolysin as active immunization and cytotoxic necrotizing factor 1 as passive immunization [42] .
Considering gender and demographic aspects of UTI susceptibility, elderly women are predisposed for (recurrent) episodes of UTI. In concordance with this, epidemiological data imply a role for oestrogen in the pathogenesis of UTI. As most of these underlying mechanisms are unknown, Lüthje et al. [43] demonstrated enhancement of the antimicrobial capacity of the urothelium and restriction of bacterial multiplication after oestrogen challenge, making this approach promising for postmenopausal women with recurrent UTIs. We have presented several new strategies of UPEC to avoid detection and elimination by the host defense and mechanisms of our immune system to counteract them ( Figure 1) . We likened the co-evolution of host and UPEC to an arms race, in which both sides attempt to gain an advantage at the expense of the other. It should be kept in mind that the clinician represents a further player in this game who acts directly against the UPEC. However, great heterogeneity in patient cohorts leads to the question of which therapy is most appropriate for a particular patient. Especially in complicated UTIs (e.g. patients with endstage renal disease or undergoing immunosuppression), increasing multidrug resistance is an important clinical concern. Therefore, in addition to microbiological characterization of the uropathogen, new approaches-e.g. vaccines or intravesical application of chemokines or inflammasome activators (Table 1 )-may become potential tools to strengthen immunological host defenses. Advances in our knowledge of the immune defense against UTI may allow the designing of therapies that work by supporting our immune system. Combined with insights into bacterial evasion strategies, the therapeutic quiver could be filled to shift the momentum in favor of the host. After this review had been submitted, another interesting study was published showing that mast cells promote shedding of infected uroepithelial cells in bacterial cystitis. The role of Mast cells in pyelonephritis is unknown [60] .
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